Evenity (Romosozumab) Bone Health and Density Impact

What Romosozumab Does to Bone Biology

Romosozumab targets sclerostin, a protein secreted by osteocytes that normally brakes the Wnt signaling pathway and limits osteoblast activity. By blocking sclerostin, romosozumab lifts that brake simultaneously on two fronts: bone formation rises sharply while bone resorption falls. This dual action is pharmacologically distinct from every other approved osteoporosis agent.

No other approved osteoporosis drug achieves meaningful formation stimulation and resorption suppression at the same time. Teriparatide and abaloparatide increase formation but also raise resorption markers. Bisphosphonates and denosumab suppress resorption without meaningfully stimulating new bone. Romosozumab's dual effect is why its BMD gains are larger and faster than those seen with either drug class alone.

Sclerostin and the Wnt Pathway

Sclerostin binds LRP5/6 co-receptors and prevents Wnt ligands from activating the canonical pathway inside osteoblast precursors [1]. When Wnt signaling is blocked, beta-catenin is degraded, osteoblastogenesis slows, and existing osteoblasts undergo apoptosis earlier than normal. Romosozumab neutralizes circulating sclerostin with high affinity, restoring Wnt-driven osteoblast proliferation and survival within days of the first injection [2].

Bone formation markers, specifically serum procollagen type I N-terminal propeptide (P1NP), rise roughly 145% above baseline by month 1 of treatment. That spike then attenuates but remains above pre-treatment values throughout the 12-month course [3].

The Resorption Side of the Equation

While formation rises, C-terminal telopeptide of type I collagen (CTX), the standard marker of osteoclast activity, falls approximately 55% below baseline within the first month [3]. The mechanism is indirect: sclerostin inhibition increases osteoprotegerin (OPG) expression by osteoblasts, which sequesters RANKL and limits osteoclast recruitment and differentiation [4].

This resorption suppression is transient. By month 9 to 12, CTX levels drift back toward baseline even with continued dosing, which is why the anabolic window closes and antiresorptive follow-on therapy is not optional but mandatory [5].

Bone Mineral Density Gains: What the Phase 3 Data Show

The FRAME trial (N=7,180 postmenopausal women, T-score between -2.5 and -3.5) randomized participants to romosozumab 210 mg SC monthly or placebo for 12 months, followed by 12 months of open-label denosumab 60 mg every 6 months in both groups [6]. The ARCH trial (N=4,093) compared romosozumab for 12 months followed by alendronate against alendronate alone for up to 24 months [7].

Lumbar Spine BMD

In FRAME, lumbar spine BMD increased 13.3% from baseline with romosozumab versus 0.0% with placebo at 12 months [6]. After the subsequent denosumab phase, the romosozumab-then-denosumab group reached 17.6% above baseline at 24 months. The placebo-then-denosumab group reached only 7.1% above baseline, a gap of 10.5 percentage points that persisted to trial end [6].

In ARCH, lumbar spine BMD rose 13.7% with romosozumab versus 7.1% with alendronate at 12 months. The advantage widened to 15.2% versus 9.8% at 24 months after transition to alendronate in the romosozumab arm [7].

Total Hip and Femoral Neck BMD

Total hip BMD gains in ARCH at 24 months were 6.2% for romosozumab-then-alendronate versus 2.8% for alendronate-alone. Femoral neck gains were 5.9% versus 3.3%, respectively [7]. These hip gains are clinically meaningful because hip fractures carry a one-year mortality of approximately 20 to 30% in older adults [8].

Trabecular and Cortical Compartments

High-resolution peripheral quantitative CT substudies from FRAME confirmed that romosozumab improved both trabecular bone volume fraction and cortical thickness at the distal radius and tibia [9]. Trabecular thickness increased while trabecular separation decreased, indicating genuine microarchitectural restoration rather than simple surface-level mineral accretion [9].

Fracture Reduction: The ARCH and FRAME Outcomes

Vertebral Fractures

In FRAME at 12 months, the incidence of new vertebral fractures was 0.5% in the romosozumab group versus 1.8% in the placebo group, a relative risk reduction of 73% (P<0.001) [6]. After both groups transitioned to denosumab, the cumulative 24-month vertebral fracture rate was 0.6% versus 2.5%, a relative risk reduction of 75% [6].

In ARCH at 24 months, new vertebral fractures occurred in 6.2% of the alendronate-only group versus 3.3% of the romosozumab-then-alendronate group, a 48% relative risk reduction (P<0.001) [7]. The number needed to treat to prevent one vertebral fracture over 24 months was approximately 34 patients.

Nonvertebral and Hip Fractures

FRAME showed a 25% reduction in nonvertebral fractures at 12 months in the overall population, though the result became more pronounced (42% reduction) in a pre-specified high-risk subgroup defined by prevalent vertebral fracture at baseline [6]. Hip fractures were numerically lower with romosozumab in FRAME but the trial was not powered to reach significance for that endpoint alone [6].

ARCH demonstrated a statistically significant 38% reduction in hip fractures with romosozumab-then-alendronate versus alendronate alone at 24 months [7]. That hip fracture result, in a head-to-head trial against an active comparator, represents some of the strongest evidence for any anabolic agent in osteoporosis.

Clinical Fracture Events

A combined analysis across ARCH and FRAME reported that romosozumab reduced clinical fractures (symptomatic vertebral plus nonvertebral) by 36% versus active comparator over 24 months [10]. The Endocrine Society's 2020 clinical practice guideline on osteoporosis cited this fracture-reduction magnitude as the basis for positioning romosozumab as a first-line anabolic option in patients at very high fracture risk [11].

As stated in that guideline: "For patients at very high risk of fracture, especially those with multiple vertebral fractures, we suggest anabolic therapy over antiresorptive therapy as initial pharmacological treatment" [11].

Cardiovascular Risk: The Black-Box Warning Explained

The FDA approved romosozumab in April 2019 with a boxed warning for increased risk of myocardial infarction, stroke, and cardiovascular death [12]. This warning emerged directly from ARCH, where serious cardiovascular events occurred in 2.5% of the romosozumab group versus 1.9% in the alendronate group during the 12-month treatment phase [7].

Why the Signal Appeared in ARCH But Not FRAME

FRAME enrolled a younger, lower-cardiovascular-risk population with a mean age of 71 years and excluded patients with prior cardiovascular events. ARCH enrolled patients with a mean age of 74 years, nearly half of whom had pre-existing cardiovascular disease [7]. The cardiovascular signal was concentrated in patients with established coronary artery disease or prior cerebrovascular events.

The absolute risk difference in ARCH was approximately 0.6 percentage points over 12 months. That figure must be weighed against a 48% vertebral fracture reduction and a 38% hip fracture reduction in the same population [7].

Contraindications and Patient Selection

Romosozumab is contraindicated in patients who have experienced an MI or stroke within the 12 months before initiating therapy [12]. The FDA label also instructs clinicians to discontinue therapy if an MI or stroke occurs during the treatment course [12].

Appropriate candidates are postmenopausal women with a lumbar spine, total hip, or femoral neck T-score at or below -2.5 plus a high 10-year fracture probability on FRAX, or a T-score at or below -3.5 regardless of other risk factors, without active cardiovascular disease [11].

Sequencing Romosozumab With Other Osteoporosis Therapies

Why Antiresorptive Follow-On Is Non-Negotiable

The anabolic window closes at 12 months. Bone formation markers return toward baseline by month 9 and resorption markers recover fully if no follow-on agent is used. An extension substudy of FRAME showed that BMD gains made during the romosozumab phase were entirely lost within 12 months of stopping without antiresorptive follow-on therapy [13]. Denosumab preserved and extended those gains; alendronate preserved most of them.

The Endocrine Society guideline explicitly recommends transitioning to a bisphosphonate or denosumab immediately after completing the 12-month romosozumab course [11].

Romosozumab After Prior Bisphosphonate Therapy

A common clinical scenario is a patient who has been on alendronate or zoledronic acid for several years and continues to fracture or shows inadequate BMD response. The STRUCTURE trial (N=436) compared romosozumab against teriparatide in women previously treated with alendronate [14]. Romosozumab increased total hip BMD by 2.6% versus a decrease of 0.6% with teriparatide at 12 months (P<0.001) [14].

This result matters because teriparatide's hip BMD performance is blunted in bisphosphonate-pretreated patients, likely due to the dense, resorption-inhibited bone surface. Romosozumab's added resorption suppression overcomes that barrier, making it the preferred anabolic in this scenario [14].

Romosozumab Before Denosumab Versus Denosumab Alone

The FRAME extension data showed that the romosozumab-then-denosumab sequence produced a 17.6% total lumbar spine BMD gain at 24 months versus 7.1% with placebo-then-denosumab [6]. The gap at the total hip was 6.9% versus 3.4% [6]. Patients who need maximum BMD gain quickly, such as those awaiting elective orthopedic surgery or with multiple recent fractures, benefit most from this front-loading approach.

A practical clinical decision framework for sequencing:

| Patient Profile | Recommended Sequence | |---|---| | Treatment-naive, very high risk, no CV disease | Romosozumab 12 months, then denosumab or zoledronic acid | | Prior bisphosphonate, still fracturing | Romosozumab 12 months, then resume bisphosphonate | | Prior teriparatide, needs hip BMD gain | Romosozumab 12 months, then bisphosphonate | | Active CV disease (MI or stroke <12 months) | Zoledronic acid or denosumab; romosozumab contraindicated | | Male osteoporosis | Off-label; evidence limited to case series |

Dosing, Administration, and Monitoring

Approved Dosing Regimen

The approved dose is two subcutaneous injections of 105 mg each (210 mg total) administered consecutively in the abdomen, thigh, or upper arm once monthly for 12 months [12]. Each prefilled syringe contains 105 mg per 1.17 mL. The injections should be given at separate sites during the same clinical visit.

No dose adjustment is required for mild-to-moderate renal impairment, but romosozumab has not been studied in patients with creatinine clearance below 30 mL/min [12]. Calcium and vitamin D adequacy must be confirmed before starting; supplementation with at least 500 mg calcium and 800 IU vitamin D daily is recommended throughout the course [12].

Baseline and On-Treatment Monitoring

Before starting, order: dual-energy X-ray absorptiometry (DXA) of lumbar spine, total hip, and femoral neck; serum calcium; 25-hydroxyvitamin D; basic metabolic panel; and a cardiovascular risk assessment including history of MI or stroke [11].

Repeat DXA at 12 months to document response before transitioning to follow-on therapy. Bone turnover markers, specifically P1NP at 1 month and CTX at 3 months, can confirm pharmacodynamic response in patients where adherence or absorption is uncertain [3].

Hypocalcemia has been reported. The FDA label notes that hypocalcemia must be corrected before initiating romosozumab [12]. Patients with severe renal impairment and those on dialysis are at highest risk [12].

Injection Site and Storage

Romosozumab must be refrigerated at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) and protected from light [12]. If removed from the refrigerator, it may be kept at room temperature up to 77 degrees Fahrenheit for a maximum of 30 days, after which it must be discarded [12]. The prefilled syringes should not be frozen or shaken.

Special Populations and Emerging Evidence

Men With Osteoporosis

Romosozumab is FDA-approved only in postmenopausal women. A phase 2 trial (N=245) in men with osteoporosis showed lumbar spine BMD increases of 12.1% at 12 months versus 1.3% with placebo and 3.4% with alendronate [15]. Fracture outcomes in men have not been studied in a phase 3 trial. Off-label use in high-risk men remains a shared decision-making conversation rather than a guideline-supported recommendation [11].

Glucocorticoid-Induced Osteoporosis

Glucocorticoid use suppresses Wnt signaling through multiple mechanisms, including upregulating sclerostin expression in osteocytes [16]. This makes sclerostin inhibition a biologically rational target in glucocorticoid-induced osteoporosis. Published case series and retrospective cohort analyses suggest BMD responses comparable to postmenopausal osteoporosis, but phase 3 fracture data are not available [16].

The American College of Rheumatology's 2022 guideline on glucocorticoid-induced osteoporosis conditionally recommends teriparatide or abaloparatide as preferred anabolic agents in this setting, with romosozumab listed as an alternative pending further trial data [17].

Breast Cancer Survivors

Aromatase inhibitor therapy in breast cancer survivors causes accelerated bone loss through estrogen deprivation. A substudy of FRAME enrolled 120 women with prior breast cancer and found BMD responses numerically similar to the overall trial population, though the substudy was underpowered for fracture outcomes [6]. No head-to-head trial against denosumab, the current standard for this population, has been completed.

Comparing Romosozumab to Other Anabolic Agents

Teriparatide (Forteo) and abaloparatide (Tymlos) are PTH-pathway anabolic agents approved for up to 24 months. Romosozumab is approved for only 12 months but produces comparable or larger lumbar spine BMD gains in less time [14]. The key numeric difference: teriparatide produces approximately 9 to 10% lumbar spine BMD gain at 18 months in treatment-naive patients; romosozumab produces 13 to 14% in 12 months [6].

At the hip, romosozumab outperforms teriparatide decisively. The STRUCTURE trial showed a 2.6% total hip gain with romosozumab versus negative 0.6% with teriparatide in alendronate-pretreated women [14]. Hip strength finite element analysis in STRUCTURE confirmed superior biomechanical improvements at the femoral neck with romosozumab [14].

Cost and access are real barriers. Romosozumab's wholesale acquisition cost exceeds $22,000 per year before prior authorization. Most payers require documented treatment failure on a bisphosphonate before approving coverage, which creates a sequencing paradox given the STRUCTURE trial's demonstration that bisphosphonate pretreatment blunts teriparatide's hip response but not romosozumab's [14].

The Endocrine Society notes: "There is evidence from clinical trials that anabolic agents are more effective than antiresorptive agents when used as initial therapy in patients with severe osteoporosis, yet access remains a challenge" [11].

Long-Term Durability After the Treatment Course

Romosozumab's BMD gains are not self-sustaining. Without antiresorptive follow-on, DXA values return toward pre-treatment baseline within 12 months of stopping [13]. With denosumab follow-on, gains made during the romosozumab year are preserved and modestly extended. With zoledronic acid, gains are similarly preserved, though the absolute values at 24 months are slightly lower than with denosumab follow-on [6, 7].

The durability question extends beyond BMD to fracture protection. In ARCH, the fracture benefit of the romosozumab-then-alendronate sequence versus alendronate alone was maintained at 24 and 36 months of follow-up, suggesting durable structural remodeling rather than a transient density artifact [7].

The 36-month ARCH extension data showed that 3.3% of the romosozumab-then-alendronate group sustained a new vertebral fracture versus 6.2% of the alendronate-only group, a sustained 48% relative risk reduction maintained well past the active romosozumab dosing period [7].